关于我们
关于HLB
领导寄语
沿革
地位
集团
制药,生物科技
造船
事业
制药,生物科技
RIVOCERANIB(阿帕替尼)
多种实体瘤
APEALEA®
特殊船舶
GRE PIPE事业
投资者关系
股价信息
公司公告
公关
IR LETTER
报刊
资料室
职业
招聘
中文
韩文
英文
Best-in-class
anticancer
drug
HLB研发的Rivocerenib追求Best-in-class
Rivoceranib为针对癌症优秀的靶向药物
Leader of Global
Pharma
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
IR Letter
About the Progress of the Global Ri...
∙ On February 26, HLB signed a binding term sheet with Adenchen Laboratories, the original developer of Rivoceranib, t...
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
Press Release
Elevar Therapeutics announces Licen...
Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating tre...
Rivoceranib showed 'complete remiss...
HLB announced that the clinical results of the Rivoceranib (Apatinib) study conducted in China confirmed several signi...
Report
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC)...
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood ves...